Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Recently, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). Concern remains regarding whether the evidence generated under the NAFLD definition can be used for MASLD. We compared the clinical profile and outcomes of NAFLD to MASLD using tertiary care- and population-based data.</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">Comparison data were obtained from our NAFLD database and the National Health and Nutrition Examination Survey (NHANES III). Clinical profiles and non-invasive tests (enhanced liver fibrosis [ELF] score, fibrosis-4 index [FIB-4] and vibration-controlled transient elastography) were compared. Mortality data were obtained from NHANES-National Death Index. All-cause mortality was assessed by Cox proportional hazards regression models and cause-specific mortality by competing risk analysis.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 6,429 patients in the NAFLD database (age: 54 ± 12 years, 42% male, BMI 35.4 ± 8.3, waist circumference 112 ± 17 cm, 52% type 2 diabetes). Average scores for ELF, FIB-4 and liver stiffness were 9.6 ± 1.2, 1.69 ± 1.24,14.0 ± 11.8 kPa, respectively; 99% met MASLD criteria; 95% met MASLD on BMI only. Predictive accuracy of ELF and FIB-4 were identical between MASLD and NAFLD. We included 12,519 eligible participants from NHANES (age 43.00 years, 47.38% male, 22.70% obese, 7.28% type 2 diabetes, 82.51% ≥1 cardiometabolic criteria). Among the NHANES study population, there was excellent concordance between MASLD and NAFLD diagnoses: Cohen's kappa coefficient: 0.968 (95% CI 0.962-0.973) with 5.29% of NAFLD cases not meeting MASLD criteria. After a median follow-up of 22.83 years, there were no mortality differences between MASLD and NAFLD diagnoses (p values ≥0.05).</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NAFLD and MASLD are similar except individuals with MASLD seem to be older with slightly higher mortality risk, likely owing to cardiometabolic risk factors. Clinical profiles and non-invasive test thresholds were also identical. These data provide evidence that NAFLD and MASLD terminologies can be used interchangeably. For the small proportion of patients with NAFLD who do not meet MASLD criteria, further consideration is needed.</AbstractText>IMPACT AND IMPLICATIONS: <AbstractText Label="IMPACT AND IMPLICATIONS" NlmCategory="UNASSIGNED">In June 2023, new terminology (MASLD) was adopted to replace the term NAFLD as a means to better describe what the liver disease is rather than what it is not, as well as to potentially reduce stigma. Given that MASLD requires at least one cardiometabolic risk factor, questions were raised as to whether this change in the definition would nullify the similarities between NAFLD and MASLD and require new evidence to be generated for MASLD. We used our NAFLD database and a US population-based database to show that the vast majority of patients with NAFLD fulfill criteria for MASLD. Non-invasive tests performed similarly in both groups. Mortality risk was slightly higher in those with MASLD, which is attributed to the presence of cardiometabolic risks. These results provide evidence that data generated in the past three decades for NAFLD can be used interchangeably for MASLD.</AbstractText>

MAFLD identifies patients with significant hepatic fibrosis better than MASLD

A Simpler Definition of MAFLD Precisely Predicts Incident Metabolic Diseases: a 7-Year Cohort Study

MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease

MAFLD predicts cardiovascular disease risk better than MASLD

From NAFLD to MASLD: when Metabolic Comorbidity Matters.

Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: results from a single-center biopsy study

Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population

Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease

Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease

Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men

Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents

From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus

Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD

Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD

MAFLD: How is it different from NAFLD?

Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol‐related liver disease

Comparing imaging modalities in the assessment of fibrosis in metabolic dysfunction‐associated steatotic liver disease

Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics